blenrep fda - Search News

News

GSK, FDA and Blenrep drug

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therapy.

· 1h

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

STAT · 3h

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

pharmaphorum3h

GSK's growth plans dented by Blenrep setback

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

Fierce Pharma17h

FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns

On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...

GlobalData on MSN2d

GSK’s Blenrep US comeback hindered by eye safety concerns

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

The Pharma Letter1d

FDA probes ocular toxicity of Blenrep as GSK seeks new indications

UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results